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Background/aim: Muslims worship by fasting from predawn (suhoor) until sunset (iftar) for 30 days in the religious month of Ramadan.
In addition to prolonged hunger, patients fasting with a diagnosis of hypothyroidism take their doses of levothyroxine (LT4) outside of
daytime fasting hours. The purpose of our study is to compare the values of hypothyroid patients which have been obtained through
thyroid function tests before and after Ramadan.
Materials and methods: Ninety-seven patients; ranging from 18 to 65 years old, who were followed with a diagnosis of hypothyroidism,
who fasted during Ramadan, and who had no change of their LT4 dose for at least 6 months were included in the study.
Results: The median serum thyroid-stimulating hormone (TSH) level of patients prior to fasting was 2.19 mIU/L, while median serum
TSH after fasting was 2.73 mIU/L. Serum TSH values after Ramadan increased significantly compared to those prior to Ramadan (P =
0.004).
Conclusion: Our study demonstrates a significant increase in serum TSH levels after Ramadan but no significant change in serum free
thyroxine (fT4) levels in hypothyroidism patients who are fasting. It may be appropriate to take precautions by making a small increase
in LT4 dose before Ramadan in some hypothyroid patients wishing to fast.
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1. Introduction
Hypothyroidism is a disease involving a metabolic
deceleration as a result of insufficiency or rarely
deficiency of thyroid hormone at the tissue level. Primary
hypothyroidism is a widespread endocrinological
disease appearing due to causes originating from
insufficiency of the thyroid gland. The basis of treatment
of hypothyroidism is the replacement by levothyroxine
(LT4). It is recommended that it should be taken with
some amount of water at least 30 min before breakfast on
an empty stomach in order to prevent drug interaction
and to increase intestinal absorption [1,2]. Because the
absorption of LT4 is disturbed by some foods and oral
drugs (cholestyramine resin, sucralfate, iron sulphate,
calcium preparations, aluminium antacids, raloxifene,
active charcoal, various soy products, and some herbal
products), taking it on an empty stomach is important [3].
It may be taken on an empty stomach while going to sleep
or 3–4 h after the last meal in some special situations [2].
While LT4 is absorbed at 80% when taken on an empty

stomach, this rate decreases to 60% when taken on a full
stomach [4].
Some Muslims throughout the world worship by
fasting from predawn (suhoor) until sunset (iftar) for 30
days in the religious month of Ramadan. Patients may
have difficulty in taking LT4 on an empty stomach during
this fasting [5]. The month of Ramadan follows the Islamic
calendar, which is 11–12 days shorter than the solar year,
so the dates of Ramadan change every year and migrate
through the seasons [6]. Fasting times of approximately
15–17 h occurred in Ramadan in 2018. Some small
metabolic and hormonal changes may occur as a result of
this prolonged fasting in Ramadan. Therefore, minimal
changes are seen in the levels of serum thyroid-stimulating
hormone (TSH), free triiodothyronine (fT3), and free
thyroxin (fT4) in healthy individuals during Ramadan.
However, it has been reported that patients with thyroid
diseases could fast without needing any adjustment of
treatment and without having any health dangers [7].
While several studies showed significant decreases in
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fT4 levels during Ramadan, it was demonstrated in some
other studies that TSH increased in males, although TSH
and fT4 levels remained within the normal ranges. It was
reported that most of those changes were reversed again
after Ramadan [8,9]. It was also shown that there is a
positive relationship between fT4 level and the number of
days fasting in females [7]. In a study conducted by Bolk
et al., lower serum TSH levels were determined in patients
taking LT4 before going to bed [10].
Interest in the medical aspects of fasting has increased
in the last 30 years [11,12]. In particular, studies on the
management of patients with diabetes mellitus have
been focused, but the studies focusing on the medical
management of thyroid diseases in relation to Ramadan
fasting are limited [7,13].
For this reason, we aimed to observe changes in thyroid
function tests before and after the month of Ramadan in
hypothyroidism patients who were fasting.
2. Materials and methods
A total of 97 patients between the ages of 18 and 65 years
old were included in the study. They had all applied to
the Clinic of Endocrinology and Metabolic Diseases,
Keçiören Education and Research Hospital of the
University of Health Sciences, in 2018, and were followed
with a diagnosis of hypothyroidism and were fasting for
Ramadan in 2018. Eighty-one patients had Hashimoto
hypothyroidism, 14 had iatrogenic hypothyroidism (6 had
postoperative papillary thyroid cancer, 8 had postoperative
benign multinodular goitre) and 2 had postradioactive
iodine ablation hypothyroidism. TSH levels were
determined individually considering the etiologic causes,
age, and comorbidities of the patients. Patients whose TSH
levels were at the determined target and, therefore, who
did not undergo LT4 dose change for the last 6 months
were included in the study. Patients regularly fasting for
at least 20 days were included in the study, and thyroid
functions (TSH, fT4) of patients within the last 1 month
before Ramadan and within the month after Ramadan
were recorded. After informed consent was obtained from
the patients meeting the inclusion criteria and attending
routine check-ups in the outpatient clinic, age, sex, daily
and weekly intake dose of LT4 treatment, fasting patterns
if they were fasting in the month of Ramadan, and time
of drug intake were recorded. Based on their biochemical
tests or examinations; patients with known malignant
disease other than thyroid papillary cancer, those
fasting while pregnant, those fasting irregularly during
Ramadan and the patients who vary their daily time of
LT4 consumption, and those using another drug together
with LT4, those receiving proton pump inhibitory therapy,
those using a known drug that effects intestinal absorption
of LT4, those suspicious with subacute thyroiditis and
with known liver or kidney failure were excluded from

the study. Patients with overt hypothyroidism (TSH ≥10
mIU/L) or overt thyrotoxicosis (TSH ≤ 0.1 mIU/L) prior to
Ramadan were not included in the study despite receiving
replacement therapy due to hypothyroidism.
Serum TSH and fT4 measurements were performed
using chemiluminescence on an automatic Abbott i2000
immunoassay device. The TSH reference interval is 0.27–4.3
mIU/L; the fT4 reference interval is 0.75–2.15 ng/dL.
2.1. Statistical analysis
Mean, standard deviation, median, minimum, and
maximum values have been given in definitive statistics
related to continuous data and percentage values have been
given for categorical variable. The Shapiro–Wilk test has
been utilized for examining the suitability of data to normal
distribution. The Mann–Whitney U test has been used for
comparing the time of drug consumption (suhoor or iftar),
and the Wilcoxon test has been used for comparing measured
TSH and fT4 values before Ramadan and after Ramadan.
The Spearman correlation coefficient has been utilized for
examining the association between daily LT4 dose and TSH.
The IBM SPSS Statistics 20 (IBM Corp, Armonk, NY, USA)
program has been used in evaluations, and P < 0.05 has been
accepted as the limit for statistical significance.
3. Results
The mean age of the 97 patients included in the study was 45
(18–65) years; 92.8% of patients were female and 7.2% were
male. The mean LT4 dose of patients was 82.14 (12.5–175)
µg/day. It was determined that 10.3% of patients took their
drugs at iftar time and 89.7% at suhoor (Table).
The median serum TSH of patients before fasting was
2.19mIU/L (0.14–9.09), and median serum TSH after
fasting was 2.73mIU/L (0.01–21.21). Serum TSH levels after
the month of Ramadan increased significantly compared
to the levels before Ramadan (P = 0.004). The median fT4
of patients before fasting was 1.11ng/dL (0.76–1.41), and
median fT4 after fasting was 1.11ng/dL (0.78–2.14). No
difference was found between fT4 values before and after the
month of Ramadan (P > 0.05) (Figure).
The median serum TSH of patients taking LT4 at iftar
time was 1.35mIU/L (0.20–4.48) before the month of
Ramadan and was 2.98mIU/L (0.79–12.84) after Ramadan.
The median TSH of patients taking LT4 at suhoor was
2.24 mIU/L (0.14–9.09) before the month of Ramadan
and 2.73mIU/L (0.01–21.21) after Ramadan. There was a
statistically significant increase in serum TSH levels in both
patients taking the drug at iftar and those taking it at suhoor
(P = 0.01 and P = 0.03, respectively). The median value of
serum TSH change from before Ramadan to after Ramadan
was 1.87mIU/L (–0.49 to 12.04) in those taking LT4 at iftar,
while it was 0.36mIU/L (–7 to 14.53) in those taking LT4 at
suhoor. No difference was found between increase of serum
TSH in those taking LT4 at iftar and those taking it at suhoor
(P > 0.05).
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Table. Demographic characteristics and laboratory parameters
of participants.
Values,
measurement results
Sex- n (%)
Female

90 (92.8)

Male

7 (7.2)

Age - years

45 (18–65)

Levothyroxine dose (µg/day)

82.14 (12.5–175)

Time of drug consumption - n (%)
Iftar

10 (10.3)

Suhoor

87 (89.7)

Serum TSH (mIU/L)
Before fasting

2.19 (0.14–9.09)

After fasting

2.73(0.01–21.21)

fT4 (ng/dL)
Before fasting

1.11 (0.76–1.41)

After fasting

1.11 (0.78–2.14)

Abbreviations: TSH: thyroid stimulating hormone, fT4: free
thyroxin.

The median fT4 of patients taking the drug at iftar time
was 1.16 ng/dL (0.85–1.38) before the month of Ramadan,
while the median serum fT4 of those taking it at iftar time
was 1.07 ng/dL (0.88–2.14) after the month of Ramadan.
The fT4 median of patients taking the drug at suhoor time
was 1.10 ng/dL (0.76–1.41) before Ramadan, while it was
1.10 ng/dL (0.78–1.72) after Ramadan. No significant
change was determined between fT4 values before and
after the month of Ramadan in patients taking LT4 at
either iftar or suhoor (P > 0.05).
From the correlation analysis, a negative correlation
was found between the daily drug dose consumed and
serum TSH values after the month of Ramadan (r = –0.257,
P = 0.01). A positive correlation was found between daily
drug dose and fT4 values after the month of Ramadan (r =
0.438, P < 0.001).
4. Discussion
This study is the first study examining the influence
of Ramadan fasting on thyroid function tests in
hypothyroidism patients who are fasting in Turkey. In
our study, we found that the median TSH level increased
significantly at the end of Ramadan, whereas fT4 did not
change.
Changes in gastric motility due to prolonged fasting
and the relieving of hunger with heavy meals may cause
fluctuations of the circadian rhythm. Therefore, deiodinase
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activity and consequently LT4 metabolism may also be
influenced [14,15]. Raza et al. argued that LT4 intake at
bedtime prevents those problems and is effective in reducing
TSH levels for this reason [7]. Among our patients, 10.3%
were taking their drugs at iftar time and 89.7% at suhoor
time, and it was seen that there was no difference between
drug intake at iftar or suhoor in terms of increases in TSH
values. No patient was taking their drugs immediately before
sleeping in our study. The increase in serum TSH values
after the month of Ramadan occurring in both patients
taking LT4 at iftar and those taking it at suhoor suggests
that this increase is caused by drug intake without letting
the stomach empty after prolonged hunger and disturbance
of drug absorption.
Karoli et al., in their study including 49 patients, stated
that the drug should be taken by waiting at least 2 h between
a meal and the consumption of the drug. However, it was
determined in the same study that approximately 75% of
the patients fasting in Ramadan did not wait long enough
between the meal and drug intake [5]. In our study, it is
thought that the increase in TSH values of fasting patients
may have been caused by their eating iftar or suhoor meals
and then not waiting long enough before drug intake.
The limited data obtained from the small number of
studies published regarding hypothyroidism and Ramadan
fasting recommend to increase the LT4 dose by 25–50 µg/day
at the beginning of the month of Ramadan and to continue
the increased dose for up to 15–20 days after Ramadan
[16]. This approach is thought to prevent fluctuations in the
TSH values of fasting patients. When our study results are
taken into consideration, we think that this approach is also
suitable for our patient population.
Some of the published literature has indicated that LT4
intake 1 h before suhoor is suitable in the month of Ramadan,
but most patients had difficulty in waking up that early and/
or missed the dose and they took their drugs together with
their meals. Drug intake on a full stomach has been found to
decrease absorption by 20% [1]. However, there are also data
suggesting that LT4 intake in the morning or in the evening
had no influence on serum TSH and quality of life [17].
Sheikh et al. showed that the mean TSH level in fasting
patients with hypothyroidism increased by 2.32 ± 3.80 mIU/L
after the month of Ramadan. While the median increase
of that parameter in our study was 1.87 mIU/L in patients
taking LT4 at iftar, it was 0.36 mIU/L in those taking LT4 at
suhoor. However, Sheikh et al. argued differently than our
thought that the increase in TSH had not been influenced by
the timing of LT4 intake and meal intervals [6].
Although hypothyroidism is a common disease, there
are a limited number of studies evaluating thyroid functions
of patients with the diagnosis of hypothyroidism who are
fasting during Ramadan. When those studies are examined
in terms of the number of patients, it is seen that they were
conducted with small numbers of individuals [5,6,9,18].
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Figure. Graph of difference for thyroid functions before and after the month of
Ramadan. Abbreviations: TSH: thyroid-stimulating hormone, fT4: free thyroxin.

We think that our study is more powerful in terms of the
ability to generalize because 97 patients were evaluated in
our study. By indicating that thyroid functions of patients
evaluated in this study were at target values in the last
6 months by using a stable dose of LT4, the absence of
a requirement for a change of LT4 dose points out the
importance of the increase in serum TSH levels that we
determined after the month of Ramadan.
Although our study was conducted in a large education
and research hospital, it is a single-centre study and may
not represent the general population. For this reason, the
generalizability of the results may be limited. The medical
histories of patients were obtained during control visits
at the outpatient clinic within 1 month after Ramadan
and the correctness of compliance by verbal declaration
may have low reliability. That is another limitation of our
study. The number of male individuals and the number
of individuals taking their drugs at iftar were low in our
study. In addition, our patients who had menstruation in
their reproductive age were also in our study population.
The change in oestrogen and progesterone levels due
to prolonged hunger and the effect of the affected
menstruation on TSH could not be evaluated so, this is an
another limiting factor for our study.
In conclusion, our study demonstrates that there is
not a significant change in fT4 levels of hypothyroidism
patients after the month of Ramadan, while an increase
occurred in TSH levels. This increase may be of particular

importance in special patient populations such as
pregnancy or papillary thyroid cancer, where TSH target
values are in the narrower range, and in groups of patients
where TSH levels are closer to the high target values.
Therefore, it may be appropriate to take precaution by
making a small increase in LT4 dose before Ramadan in
some hypothyroid patients wishing to fasting. However,
further research is needed to fully understand in which
patients and in what amount the LT4 dose increase will
be appropriate and at what time it is appropriate to take
this dose.
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